Company Profile
Pacific Biosciences Stock Price, News & Analysis
- Ticker:
- PACB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.17 USD (-10.38%)
Close
Last updated: August 6, 2026
491M USD
Market cap
Why the stock is moving
Following the latest company update, “PacBio Appoints Mark Van Oene as President and Chief Executive Officer”, PACB closed down 10.4% at $1.17 on Aug 6, 2026. The move occurred in the trading session associated with this company update.
Company overview
Long-Read Sequencing
Pacific Biosciences, or PacBio, develops high-accuracy long-read sequencing systems used in research and clinical genomics. Its HiFi technology reads long DNA fragments while maintaining high base-level accuracy.
Sequencing Platforms
The company's instrument portfolio includes high-throughput Revio systems and benchtop Vega systems. Revenue combines instrument placements with recurring consumables, service and software. PacBio technology is used for whole-genome sequencing, rare-disease analysis, population genomics, microbial research and other applications where resolving structural variation and complex genomic regions is important.
Future catalysts
PacBio's catalysts are Revio placements, HiFi sequencing adoption, and continued traction in clinical and translational workflows. The company needs to show that the high-accuracy platform is becoming sticky, not just interesting.
Recent news
- 01
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
Source: Pacific Biosciences
- 02
PacBio Announces Second Quarter 2026 Financial Results
Source: Pacific Biosciences
- 03
PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
Source: Pacific Biosciences
- 04
PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Source: Pacific Biosciences
- 05
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
Source: Pacific Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pacific Biosciences (PACB)?
Pacific Biosciences (PACB) most recently closed at 1.17 USD, a -10.38% move versus the previous session.
What is the market cap of Pacific Biosciences (PACB)?
Pacific Biosciences currently has a market capitalization of 491M USD on BioPharmSignal.
What does Pacific Biosciences do?
Long-Read Sequencing Pacific Biosciences, or PacBio, develops high-accuracy long-read sequencing systems used in research and clinical genomics. Its HiFi technology reads long DNA fragments while maintaining high base-level accuracy. Sequencing Platforms The company's instrument portfolio includes high-throughput Revio systems and benchtop Vega systems....
On which exchange is PACB stock listed?
Pacific Biosciences (PACB) is associated with NASDAQ, United States, Biopharma.
What is Long-Read?
Long-Read Sequencing Pacific Biosciences, or PacBio, develops high-accuracy long-read sequencing systems used in research and clinical genomics.
Which conditions is Pacific Biosciences targeting with Long-Read?
Long-Read Sequencing Pacific Biosciences, or PacBio, develops high-accuracy long-read sequencing systems used in research and clinical genomics. Its HiFi technology reads long DNA fragments while maintaining high base-level accuracy. Sequencing Platforms The company's instrument portfolio includes high-throughput Revio systems and benchtop Vega systems....
How does Pacific Biosciences describe recent progress with Long-Read?
PacBio's catalysts are Revio placements, HiFi sequencing adoption, and continued traction in clinical and translational workflows. The company needs to show that the high-accuracy platform is becoming sticky, not just interesting.
What is Sequencing?
Long-Read Sequencing Pacific Biosciences, or PacBio, develops high-accuracy long-read sequencing systems used in research and clinical genomics.